Description
A glucocorticoid and an agonist of glucocorticoid receptors (EC50 = 45.7 pM in a transactivation assay); selective for glucocorticoid over mineralocorticoid receptors (EC50 = 7,620 pM); inhibits LPS-induced TNF-α release from human PBMCs (IC500 = 0.96 nM); reduces levels of IL-1β and eotaxin in the lungs and the number of eosinophils and neutrophils in BALF in a rat model of ovalbumin-induced airway inflammation at 3 mg/kg; intracolonic administration decreases colon wet weight and colonic MPO activity in a rat model of oxazolone-induced colitis
Formal name: 16α,17-[butylidenebis(oxy)]-11β,21-dihydroxy-pregna-1,4-diene-3,20-dione
Synonyms:
Molecular weight: 430.5
CAS: 51333-22-3
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Endocrinology & Metabolism|Hormones & Receptors|Glucocorticoids & Mineralocorticoids||Research Area|Immunology & Inflammation|Allergy||Research Area|Immunology & Inflammation|Gastric Disease|Crohn’s Disease||Research Area|Immunology & Inflammation|Gastric Disease|Ulcerative Colitis||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Immunology & Inflammation|Pulmonary Diseases|Asthma